Cytology for PD-L1 testing: A systematic review.
| Title: | Cytology for PD-L1 testing: A systematic review. |
|---|---|
| Authors: | Gosney JR; Department of Cellular Pathology, Royal Liverpool University Hospital, Duncan Building, Prescot Street, Liverpool L8 7XP, United Kingdom. Electronic address: john.gosney@rlbuht.nhs.uk.; Boothman AM; Precision Medicine, Oncology R&D, AstraZeneca, Cambridge SG8 6HB, UK. Electronic address: Anne-Marie.Boothman@astrazeneca.com.; Ratcliffe M; Precision Medicine, Oncology R&D, AstraZeneca, Cambridge SG8 6HB, UK. Electronic address: marianne.ratcliffe1@astrazeneca.com.; Kerr KM; Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZD, UK. Electronic address: k.kerr@abdn.ac.uk. |
| Source: | Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2020 Mar; Vol. 141, pp. 101-106. Date of Electronic Publication: 2020 Jan 13. |
| Publication Type: | Journal Article; Systematic Review |
| Language: | English |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE |
| Imprint Name(s): | Publication: Limerick : Elsevier Scientific Publishers; Original Publication: Amsterdam, The Netherlands : Elsevier, c1985- |
| MeSH Terms: | B7-H1 Antigen/*metabolism ; Biomarkers, Tumor/*metabolism ; Cytodiagnosis/*methods ; Lung Neoplasms/*diagnosis; Lung Neoplasms/metabolism ; Humans ; Prognosis |
| Abstract: | Evaluation of tumoral programmed cell death ligand-1 (PD-L1) expression is standard practice for patients with advanced non-small-cell lung cancer (NSCLC) who may be candidates for treatment targeting the programmed cell death-1 (PD-1)/PD-L1 pathway. Currently, all of the commercially available immunohistochemistry assays have been validated for use with histology specimens although, in routine clinical practice, approximately 30-40 % of patients with advanced NSCLC have only cytology specimens available for diagnosis, staging, and biomarker analysis. This systematic review evaluated the success rate, concordance, and clinical utility of using cytology specimens to assess tumor PD-L1 expression levels compared with histology specimens from patients with advanced NSCLC. EMBASE and PubMed database searches identified 142 unique, relevant publications, of which 15 met the inclusion criteria for at least one analysis. In 709 specimens, across seven publications, the proportion of cytology specimens evaluable for PD-L1 testing was 92.0 %. Among nine studies eligible for concordance analysis between cytology and histology specimens at a PD-L1 tumor cell expression cutoff of ≥50 %, overall percentage agreement was 89.7 % (n = 428), 72.0 % for positive percentage agreement (n = 218), and 95.0 % for negative percentage agreement (n = 258); results using a tumor PD-L1 expression cutoff of ≥1 % were similar. Our analyses suggest that using cytology specimens to assess PD-L1 expression is feasible, with good levels of concordance between cytology and histology specimens using PD-L1 tumor cell expression cutoffs of ≥1 % and ≥50 %. In conclusion, there is no convincing evidence that cytology specimens are inadequate or inferior to histology specimens for assessing PD-L1 expression in patients with NSCLC.; (Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.) |
| Contributed Indexing: | Keywords: Cytology; Fine needle aspirate; Immunohistochemistry; NSCLC; PD-L1; Systematic review |
| Substance Nomenclature: | 0 (B7-H1 Antigen); 0 (Biomarkers, Tumor); 0 (CD274 protein, human) |
| Entry Date(s): | Date Created: 20200203 Date Completed: 20210406 Latest Revision: 20210406 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.lungcan.2020.01.010 |
| PMID: | 32007657 |
| Database: | MEDLINE |
Journal Article; Systematic Review